Search results for "abnormalities"

showing 10 items of 638 documents

Three-dimensional ultrasonography in prenatal diagnosis

1995

Within the past five years, 3D ultrasonography has developed to the degree that it offers both the patient and the examiner an entirely new visual experience in prenatal diagnosis. With the system described here (Kretz-technik, Austria), any desired plane can be displayed within the stored volume, and within seconds a high-quality 3D surface or transparent image can be calculated and displayed on the ultrasound monitor without need for an external workstation. All of this can be performed routinely in the clinical setting. Since 1989 we have routinely examined a total of 458 fetuses (242 normal and 216 with anomalies) between 16 and 38 weeks of gestation, supplementing our conventional 2D u…

business.industryUltrasoundObstetrics and GynecologyImage processingOligohydramniosPrenatal diagnosisImage planemedicine.diseaseStereo displayUltrasonography PrenatalCongenital AbnormalitiesFetal DiseasesFetusPregnancyPediatrics Perinatology and Child HealthImage Processing Computer-AssistedmedicineHumansFemalebusinessNuclear medicineSurface reconstructionVolume (compression)jpme
researchProduct

No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Data…

2021

Background. Lynch syndrome is the most common genetic predisposition for hereditary cancer. Carriers of pathogenic changes in mismatch repair (MMR) genes have an increased risk of developing colorectal (CRC), endometrial, ovarian, urinary tract, prostate, and other cancers, depending on which gene is malfunctioning. In Lynch syndrome, differences in cancer incidence (penetrance) according to the gene involved have led to the stratification of cancer surveillance. By contrast, any differences in penetrance determined by the type of pathogenic variant remain unknown. Objective. To determine cumulative incidences of cancer in carriers of truncating and missense or aberrant splicing pathogenic …

cancer incidence0302 clinical medicineMalalties hereditàriesMissense mutation8Q23.3CàncerCancerGenetics0303 health sciencesmedicine.diagnostic_testFactors de risc en les malaltiesMISMATCH REPAIR GENESRMLH1General MedicinePenetranceLynch syndrome3. Good healthsyöpägeenit030220 oncology & carcinogenesisMedicinesyöpätauditilmaantuvuusGenetic diseasescongenital hereditary and neonatal diseases and abnormalitiesmissense11Q23.1Risk factors in diseasesCANCER-RISKMLH1Articleaberrant splicing03 medical and health sciencesAGEmedicineGenetic predispositionddc:610<i>MSH2</i>Lynchin oireyhtymäpenetrance030304 developmental biologyGenetic testingMLH1; MSH2; penetrance; cancer incidence; truncating; missense; aberrant splicing; Lynch syndromeperinnölliset tauditbusiness.industryMUTATIONSHMSH2Cancernutritional and metabolic diseasesmedicine.diseasedigestive system diseasesMSH2Lynch syndromeMSH23121 General medicine internal medicine and other clinical medicine<i>MLH1</i>businesstruncating
researchProduct

DOUBLE TRANSVERSE FORAMEN IN INFANTILE CERVICAL VERTEBRAE OF THE LATE 17TH AND EARLY 18TH CENTURIES. Doble foramen transverso en las vértebras infant…

2016

La presencia de doble foramen transverso es una variante anatómica que se observa con frecuencia en el raquis cervical inferior y que presenta implicaciones clínicas en relación con la arteria vertebral. Aunque en la actualidad existe cierta controversia acerca de si el origen de esta variante cervical es congénito o adquirido, y a pesar de que la presencia de doble foramen transverso en población infantil descartaría un origen degenerativo-artrósico, se encuentra una falta de información acerca de su presencia en vértebras cervicales infantiles. En este sentido, nuestro objetivo ha sido analizar la presencia de doble foramen transverso en vértebras cervicales infantiles procedentes de rest…

childcongenital abnormalitiesbusiness.industryGeography Planning and Developmentlcsh:Rniñolcsh:MedicineAnatomyDevelopmentspineraquismedicine.anatomical_structureSpainForamenlcsh:PathologyMedicinebusinessCervical vertebraelcsh:RB1-214Revista Argentina de Anatomía Clínica
researchProduct

Does Hysteroscopic Dissection of Partial Uterine Septum Represent a Risk Factor for Placental Abnormalities in Subsequent Pregnancy Compared with Con…

2022

Background: Hysteroscopic septum dissection (HSD) is thought to improve fertility and pregnancy outcomes. However, the available literature suggests that uterine surgery can cause placental abnormalities in subsequent pregnancies. Methods: A case–control study was performed at the University Medical Center of Ljubljana, Department of Human Reproduction, from 1 January 2016 to 31 December 2018. The primary outcome was the association between HSD and the occurrence of placental abnormalities. We included women who underwent HSD due to infertility. Age-matched women who underwent hysteroscopic surgery for other issues were considered as controls. In addition, we divided the groups according to…

congenital uterine anomalies; uterine septum dissection; placental abnormalities; neonatal outcome; IVF/ICSI; hysteroscopy; complicationsComplicationsUterine septum dissectionIVF/ICSIGeneral MedicineCongenital uterine anomaliesHysteroscopyNeonatal outcomeSettore MED/40 - Ginecologia E OstetriciaPlacental abnormalities
researchProduct

Impact of Fragile X Syndrome on Their Families

2020

espanolEl objetivo del presente estudio es describir las alteraciones conductuales y emocionales en el sindrome de X fragil (SXF) y analizar las reperecusiones de tener un miembro con SXF en diferentes aspectos del funcionamiento familiar. Participaron 79 padres con un miembro con SXF y 80 padres con un miembro con desarrollo tipico. Los resultados mostraron que entre el 17% y el 66% de los ninos y adolescentes con SXF mostraron trastornos conductuales y emocionales significativos y menos comportamientos prosociales. Ademas, despues de controlar las dificultades emocionales y de comportamiento, nuestros resultados mostraron que las familias afectadas por SXF experimentaron un impacto mas ne…

congenital hereditary and neonatal diseases and abnormalities030506 rehabilitationfamilySocial Psychologyfragile x syndromeFamily functioninglcsh:BF1-990trastorno de la conductaanálisis comparativo03 medical and health sciencesDevelopmental and Educational Psychologymedicine0501 psychology and cognitive sciencessituación familiar05 social sciencesSíndrome X Frágil (SXF)vida familiarmedicine.diseaseSindrome deFragile X syndromeClinical Practicelcsh:Psychologylcsh:Bimpactlcsh:Philosophy. Psychology. Religion0305 other medical sciencePsychologyHumanitiestrastorno emocional050104 developmental & child psychologyPsicología Educativa
researchProduct

"Table 3" of "Cross-sections and leptonic forward-backward asymmetries from the Z0 running of LEP."

2000

Hadronic cross section measured with the 1995 data. Additional systematic error of 0.10 PCT (efficiencies and backgrounds) and 0.11 PCT (absolute luminosity).

congenital hereditary and neonatal diseases and abnormalities89.438-92.965E+ E- --&gt; HADRONSE+ E- Scatteringparasitic diseasesIntegrated Cross SectionExclusiveCross SectionR measurementbacterial infections and mycosesSIGhormones hormone substitutes and hormone antagonists
researchProduct

Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses.

2004

Glycosaminoglycans are accumulated in both mucopolysaccharidoses (MPS) and mucolipidoses (ML). MPS I, II, III and VII and ML II and ML III patients cannot properly degrade heparan sulphate (HS). In spite of the importance of HS storage in the metabolic pathway in these diseases, blood and urine HS levels have not been determined systematically using a simple and economical method. Using a new ELISA method using anti-HS antibodies, HS concentrations in blood and urine were determined in MPS and ML II and ML III patients. HS concentrations were determined in 156 plasma samples from MPS I (n = 23), MPS II (n = 26), MPS III (n = 24), MPS IV (n = 62), MPS VI (n = 5), MPS VII (n = 5), ML II (n = …

congenital hereditary and neonatal diseases and abnormalitiesAdolescentMucopolysaccharidosisEnzyme-Linked Immunosorbent AssayUrineSignificant elevationGlycosaminoglycanchemistry.chemical_compoundMucolipidosesGeneticsmedicineHumansElisa methodskin and connective tissue diseasesChildGenetics (clinical)Chromatography High Pressure LiquidGlycosaminoglycansDose-Response Relationship DrugChemistryHeparinInfant Newbornnutritional and metabolic diseasesMucolipidosesInfantHeparan sulfateMucopolysaccharidosesmedicine.diseaseMolecular biologyDose–response relationshipBiochemistryChemistry ClinicalChild PreschoolHeparitin SulfateBiomarkersJournal of inherited metabolic disease
researchProduct

Pluripotent stem cells to model Hutchinson-Gilford progeria syndrome (HGPS): Current trends and future perspectives for drug discovery

2015

Progeria, or Hutchinson-Gilford progeria syndrome (HGPS), is a rare, fatal genetic disease characterized by an appearance of accelerated aging in children. This syndrome is typically caused by mutations in codon 608 (p.G608G) of the LMNA, leading to the production of a mutated form of lamin A precursor called progerin. In HGPS, progerin accumulates in cells causing progressive molecular defects, including nuclear shape abnormalities, chromatin disorganization, damage to DNA and delays in cell proliferation. Here we report how, over the past five years, pluripotent stem cells have provided new insights into the study of HGPS and opened new original therapeutic perspectives to treat the disea…

congenital hereditary and neonatal diseases and abnormalitiesAgingDiseaseBiologymedicine.disease_causeModels BiologicalBiochemistryLMNAProgeriaPluripotent stem cellsDrug DiscoverymedicineHumansInduced pluripotent stem cellMolecular BiologyGeneticsProgeriaMutationintegumentary systemDrug discoverynutritional and metabolic diseasesLamin Type Amedicine.diseaseProgerinChromatinAgeingNeurologyMutationCancer researchBiotechnologyAgeing Research Reviews
researchProduct

Epigenetic involvement in Hutchinson-Gilford progeria syndrome: a mini-review.

2013

Hutchinson-Gilford progeria syndrome (HGPS) is a rare human genetic disease that leads to a severe premature ageing phenotype, caused by mutations in the &lt;i&gt;LMNA&lt;/i&gt; gene. The &lt;i&gt;LMNA&lt;/i&gt; gene codes for lamin-A and lamin-C proteins, which are structural components of the nuclear lamina. HGPS is usually caused by a de novo &lt;i&gt;C1824T&lt;/i&gt; mutation that leads to the accumulation of a dominant negative form of lamin-A called progerin. Progerin also accumulates physiologically in normal ageing cells as a rare splicing form of lamin-A transcripts. From this perspective, HGPS cells seem to be good candidates for the study of the physiological mechanisms of ageing…

congenital hereditary and neonatal diseases and abnormalitiesAgingEuchromatinSettore BIO/11 - Biologia MolecolarecernaBiologySettore MED/13 - EndocrinologiaEpigenesis GeneticLMNAHistonesAdenosine TriphosphateProgeriaHGPS Progeria; epigenetics; chromatin; cernamedicineHumansEpigeneticsProtein PrecursorsChildEpigenesisGeneticsCell NucleusProgeriaintegumentary systemnutritional and metabolic diseasesNuclear ProteinsDNA Methylationmedicine.diseaseProgerinChromatin Assembly and DisassemblyLamin Type AChromatinCell biologySettore BIO/18 - GeneticaMicroRNAsSettore MED/03 - Genetica MedicaMutationHGPS ProgeriachromatinNuclear laminaGeriatrics and GerontologyepigeneticMi-2 Nucleosome Remodeling and Deacetylase ComplexGerontology
researchProduct

Cytoprotective effects of the antioxidant phytochemical indicaxanthin in beta-thalassemia red blood cells

2006

Antioxidant phytochemicals are investigated as novel treatments for supportive therapy in beta-thalassemia. The dietary indicaxanthin was assessed for its protective effects on human beta-thalassemic RBCs submitted in vitro to oxidative haemolysis by cumene hydroperoxide. Indicaxanthin at 1.0-10 microM enhanced the resistance to haemolysis dose-dependently. In addition, it prevented lipid and haemoglobin (Hb) oxidation, and retarded vitamin E and GSH depletion. After ex vivo spiking of blood from thalassemia patients with indicaxanthin, the phytochemical was recovered in the soluble cell compartment of the RBCs. A spectrophotometric study showed that indicaxanthin can reduce perferryl-Hb ge…

congenital hereditary and neonatal diseases and abnormalitiesAntioxidantErythrocytesPyridinesmedicine.medical_treatmentindicaxanthinphytochemicalBiochemistryHemolysisAntioxidantschemistry.chemical_compoundHemoglobinsAntioxidants betalainhemic and lymphatic diseasesSettore BIO/10 - BiochimicamedicineBenzene DerivativesHumansVitamin ETraditional medicineDose-Response Relationship DrugChemistrybeta-ThalassemiaBeta thalassemiaGeneral Medicinemedicine.diseaseLipid MetabolismGlutathionehaemoglobinBetaxanthinsPhytochemicalBiochemistryCytoprotectionSpectrophotometryCase-Control StudiesHeminAntioxidants betalains haemoglobin indicaxanthin phytochemicals red blood cellsIndicaxanthinOxidation-Reductionred blood cells
researchProduct